

John L Marshall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4047154/publications.pdf>

Version: 2024-02-01

160
papers

5,380
citations

117453

34
h-index

95083

68
g-index

162
all docs

162
docs citations

162
times ranked

8159
citing authors

#	ARTICLE	IF	CITATIONS
1	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 271-279.	3.0	27
2	Association of Homologous Recombinationâ€“DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 227-236.	1.9	4
3	The Essentials of Multiomics. <i>Oncologist</i> , 2022, 27, 272-284.	1.9	11
4	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 198-209.	1.9	18
5	Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 246-246.	0.8	0
6	Molecular Characterization of <i>KRAS</i> Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2704-2714.	3.2	57
7	Comprehensive Analysis of R-Spondin Fusions and <i>RNF43</i> Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1863-1870.	3.2	16
8	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. <i>Oncogene</i> , 2022, 41, 3455-3460.	2.6	19
9	The current state of molecular profiling in gastrointestinal malignancies. <i>Biology Direct</i> , 2022, 17, .	1.9	5
10	Abstract 1231: Prognostic and predictive drug-induced gene signatures for colorectal cancer patients personalized based on p53 status and treatment with FOLFOX, 5-FU, oxaliplatin, or irinotecan. <i>Cancer Research</i> , 2022, 82, 1231-1231.	0.4	0
11	Clinical Validation of a Machine-learningâ€“derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1174-1183.	3.2	28
12	SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma. <i>Theranostics</i> , 2021, 11, 4232-4250.	4.6	26
13	A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies. <i>Cancer Medicine</i> , 2021, 10, 1944-1954.	1.3	12
14	Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. <i>Scientific Reports</i> , 2021, 11, 5639.	1.6	1
15	Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type. <i>Translational Oncology</i> , 2021, 14, 101016.	1.7	22
16	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.	3.2	24
17	Clinical and Functional Characterization of Atypical <i>KRAS</i> / <i>NRAS</i> Mutations in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4587-4598.	3.2	14
18	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021, 40, 4894-4905.	2.6	19

#	ARTICLE	IF	CITATIONS
19	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. <i>Cancer Treatment Reviews</i> , 2021, 98, 102218.	3.4	33
20	Global mapping of cancers: The Cancer Genome Atlas and beyond. <i>Molecular Oncology</i> , 2021, 15, 2823-2840.	2.1	55
21	Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic. <i>Current Treatment Options in Oncology</i> , 2021, 22, 93.	1.3	5
22	Evaluating the impact of age on immune checkpoint therapy biomarkers. <i>Cell Reports</i> , 2021, 36, 109599.	2.9	27
23	Molecular characterization of squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2423-2437.	0.6	7
24	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 95.	2.3	9
25	Excitement for our future. <i>Oncotarget</i> , 2021, 12, 2307-2307.	0.8	0
26	Cases in the management of metastatic colorectal cancer: use of regorafenib as a bridge to chemotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 6, 1-8.	0.3	0
27	Neuroendocrine tumor causing ureteral obstruction in a patient with prior ileal conduit.. <i>Canadian Journal of Urology</i> , 2021, 28, 10953-10955.	0.0	0
28	Considerations in the management of younger patients with colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 16, 1-20.	0.3	0
29	Addressing the needs of younger patients with colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 16, 9-11.	0.3	0
30	Considerations in the management of younger patients With colorectal cancer: Q&A.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 16, 15-17.	0.3	0
31	Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, 197-202.	1.9	12
32	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020, 140, 119-129.	1.3	37
33	Cancer predictive studies. <i>Biology Direct</i> , 2020, 15, 18.	1.9	37
34	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2634-2640.	1.9	14
35	A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5092-5101.	3.2	28
36	A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. <i>Journal of Pancreatic Cancer</i> , 2020, 6, 45-54.	1.6	15

#	ARTICLE	IF	CITATIONS
37	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020, 26, 5943-5951.	3.2	55
38	Liquid biopsies and cancer omics. <i>Cell Death Discovery</i> , 2020, 6, 131.	2.0	52
39	Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit. <i>Colorectal Cancer</i> , 2020, 9, .	0.8	12
40	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	1.7	10
41	Medical Oncologistsâ€™ Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. <i>Oncologist</i> , 2020, 25, 229-234.	1.9	9
42	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 1320-1328.	0.8	16
43	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020, 5, e000682.	2.0	64
44	Relationship between <scp>MLH1</scp>, <scp>PMS2</scp>, <scp>MSH2</scp> and <scp>MSH6</scp> gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. <i>International Journal of Cancer</i> , 2020, 147, 2948-2956.	2.3	102
45	How to incorporate a chemo-free interval into the management of metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 16, 1-24.	0.3	0
46	Third-line treatments for the management of metastatic colorectal cancer: why to change the mechanism of action after frontline chemotherapy, and insights into management during the COVID-19 pandemic. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 16, 6-14.	0.3	0
47	How to incorporate a chemo-free interval into the management of metastatic colorectal cancer: discussion. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 16, 20-21.	0.3	0
48	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019, 24, 319-326.	1.9	29
49	Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 652-662.	0.6	106
50	Colon Cancer in Young Adults: Trends and Their Implications. <i>Current Oncology Reports</i> , 2019, 21, 3.	1.8	74
51	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3096-3103.	3.2	65
52	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203
53	Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGP)s.. <i>Journal of Clinical Oncology</i> , 2019, 37, 505-505.	0.8	1
54	Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 60-60.	0.8	5

#	ARTICLE	IF	CITATIONS
55	Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.. Journal of Clinical Oncology, 2019, 37, 606-606.	0.8	5
56	Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon.. Journal of Clinical Oncology, 2019, 37, 63-63.	0.8	0
57	Biomarkers for immune therapy in gastrointestinal cancers. Clinical Advances in Hematology and Oncology, 2019, 17, 109-119.	0.3	4
58	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, 2018, 16, 805-812.	1.5	169
59	A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer, 2018, 124, 2337-2346.	2.0	47
60	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nature Communications, 2018, 9, 1219.	5.8	20
61	A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology, 2018, 81, 587-596.	1.1	66
62	Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Medicine, 2018, 7, 746-756.	1.3	348
63	Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2018, 49, 116-123.	0.6	22
64	Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precision Oncology, 2018, 2018, 1-13.	1.5	215
65	Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genetics, 2018, 228-229, 131-142.	0.2	5
66	Underuse of exon mutational analysis for gastrointestinal stromal tumors. Journal of Surgical Research, 2018, 231, 43-48.	0.8	4
67	Molecular Variances Between Right- and Left-sided Colon Cancers. Current Colorectal Cancer Reports, 2018, 14, 152-158.	1.0	5
68	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. Oncologist, 2018, 23, 1319-1327.	1.9	131
69	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 12106-12106.	0.8	2
70	Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors.. Journal of Clinical Oncology, 2018, 36, 3572-3572.	0.8	6
71	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. Journal of Clinical Oncology, 2018, 36, 4032-4032.	0.8	4
72	Comprehensive molecular profiling of paired patient samples of primary and metastatic (met) pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2018, 36, 4114-4114.	0.8	2

#	ARTICLE	IF	CITATIONS
73	A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.. Journal of Clinical Oncology, 2018, 36, TPS4150-TPS4150.	0.8	2
74	Neutrophil-to-lymphocyte ratio as a prognostic marker for metastatic pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 251-251.	0.8	1
75	Molecular characterization of intestinal (IS) and diffuse subtypes (DS) of gastric adenocarcinomas.. Journal of Clinical Oncology, 2018, 36, 60-60.	0.8	0
76	Molecular profiling to predict outcomes following Y90 radioembolization for metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 686-686.	0.8	0
77	Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States.. Journal of Clinical Oncology, 2018, 36, 376-376.	0.8	6
78	Does stereotactic body radiation therapy have a role in oligoprogressive metastatic colorectal cancer?. Journal of Clinical Oncology, 2018, 36, 755-755.	0.8	0
79	Differences in molecular profiles of males and females with colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 623-623.	0.8	0
80	Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database.. Journal of Clinical Oncology, 2018, 36, 724-724.	0.8	0
81	Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database.. Journal of Clinical Oncology, 2018, 36, 728-728.	0.8	14
82	Association of increased T cell infiltrates in the invasive margin with relapse-free survival in patients with cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2018, 36, e15001-e15001.	0.8	0
83	Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 3577-3577.	0.8	0
84	Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).. Journal of Clinical Oncology, 2018, 36, 3611-3611.	0.8	0
85	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. Journal of Clinical Oncology, 2018, 36, 4098-4098.	0.8	0
86	Comprehensive tumor genomic testing in the community oncology setting in the United States.. Journal of Clinical Oncology, 2018, 36, e24304-e24304.	0.8	0
87	Profiling for microsatellite instability (MSI) and mismatch repair (MMR) among patients with colon cancer in real world settings.. Journal of Clinical Oncology, 2018, 36, e15622-e15622.	0.8	0
88	Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genetics, 2017, 218-219, 39-50.	0.2	42
89	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, 86356-86368.	0.8	147
90	Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 3338-3346.	0.8	69

#	ARTICLE	IF	CITATIONS
91	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 1079-1099.	0.6	34
92	Characterization of tumor mutation load (TML) in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11517-11517.	0.8	19
93	Impact of patient age on molecular alterations in left-sided colorectal tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3592-3592.	0.8	4
94	Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4071-4071.	0.8	107
95	Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. <i>Oncotarget</i> , 2017, 8, 37923-37934.	0.8	23
96	Molecular characteristics of hepatocellular carcinomas from different age groups. <i>Oncotarget</i> , 2017, 8, 101591-101598.	0.8	4
97	Colorectal cancer: Impact of primary tumor location on genetic alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3578-3578.	0.8	1
98	Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2016, 11, 807-814.	1.7	4
99	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. <i>Molecular Therapy</i> , 2016, 24, 1150-1158.	3.7	114
100	Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. <i>Oncology Letters</i> , 2016, 11, 1645-1650.	0.8	20
101	Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 699-706.	1.2	16
102	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv437.	3.0	20
103	Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. <i>Cancer Immunology Research</i> , 2016, 4, 419-430.	1.6	247
104	Challenges That Hinder the Translation of Clinical Advances Into Practice: Results From an International Assessment in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 54-66.	1.0	7
105	A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 116-28.	0.3	7
106	Approach to the medical management of surgically resectable gastric cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 129-35.	0.3	0
107	Trifluridine/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 630-8.	0.3	6
108	Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. <i>Scientific Reports</i> , 2015, 5, 12122.	1.6	58

#	ARTICLE	IF	CITATIONS
109	Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1073-1079.	1.1	31
110	Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1309-1314.	1.1	44
111	Rechallenging 5-Fluorouracil in a Patient With Capecitabine-Induced Ventricular Fibrillation. <i>Clinical Colorectal Cancer</i> , 2015, 14, 198-201.	1.0	6
112	Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer. <i>Current Cancer Drug Targets</i> , 2015, 14, 775-793.	0.8	33
113	A Phase 1 Study of 131I-CLR1404 in Patients with Relapsed or Refractory Advanced Solid Tumors: Dosimetry, Biodistribution, Pharmacokinetics, and Safety. <i>PLoS ONE</i> , 2014, 9, e111652.	1.1	25
114	Losing Sight of Our Primary Target: Curing Cancer. <i>Seminars in Oncology</i> , 2014, 41, 143-144.	0.8	0
115	Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 332-340.	0.5	12
116	Conference Scene: Fighting a smarter war against cancer. <i>Colorectal Cancer</i> , 2014, 3, 131-133.	0.8	1
117	Maintenance therapy in metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 388-90.	0.3	0
118	A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 399-408.	1.2	41
119	Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. <i>Future Oncology</i> , 2013, 9, 271-281.	1.1	16
120	Microsatellite instability in colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 659-61.	0.3	2
121	Implementation of a Performance Improvement Initiative in Colorectal Cancer Care. <i>Journal of Oncology Practice</i> , 2012, 8, 309-314.	2.5	12
122	The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.. <i>Journal of Clinical Oncology</i> , 2012, 30, 678-678.	0.8	5
123	Philanthropy, Advocacy and Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 290.	1.0	1
124	Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 193-198.	1.0	2
125	Safety of capecitabine: a review. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 831-841.	1.0	73
126	Risk assessment in Stage II colorectal cancer. <i>Oncology</i> , 2010, 24, 9-13.	0.4	26

#	ARTICLE	IF	CITATIONS
127	Fighting a smarter war on cancer. <i>Oncology</i> , 2010, 24, 193-4.	0.4	0
128	ISGIO and the Future of GI Oncology: A Very Different Society Making a Very Important Difference. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 1-2.	0.8	0
129	Too much information. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 43-4.	0.8	0
130	Heading in the right direction. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 89.	0.8	0
131	ISGIO: Setting the Standard of Care for the Future. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 133.	0.8	0
132	Accomplishments in 2008 in the adjuvant treatment of colon cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, S2-7.	0.8	1
133	Integrating Targeted Agents into Therapeutic Regimens for Patients with Resectable Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, S63-S66.	1.0	0
134	Carcinoembryonic antigen as a vaccine target. <i>Expert Review of Vaccines</i> , 2008, 7, 987-993.	2.0	12
135	Health care reform: will we pass the external review?. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 53.	0.8	0
136	Managing potentially resectable metastatic colon cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, S23-6.	0.8	8
137	More fanfare for metastatic colon cancer resections. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, 28.	0.8	2
138	Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, 146-54.	0.8	26
139	Bevacizumab in the treatment of colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 8-9.	0.3	6
140	The development of novel agents for the treatment of colorectal cancer: a critical review of current practice and some suggestions for the future. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 167-72.	0.3	3
141	Clinical experiences with G17DT in gastrointestinal malignancies. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 487-492.	1.1	4
142	Optimum Use of Biologics and Role of Maintenance Therapy in Colon Cancer. <i>Seminars in Oncology</i> , 2006, 33, 33-35.	0.8	16
143	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. <i>Cancer</i> , 2006, 107, 1207-1218.	2.0	165
144	The Role of Bevacizumab as First-line Therapy for Colon Cancer. <i>Seminars in Oncology</i> , 2005, 32, 43-47.	0.8	42

#	ARTICLE	IF	CITATIONS
145	Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen-Expressing Carcinomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 720-731.	0.8	290
146	Novel vaccines for the treatment of gastrointestinal cancers. <i>Oncology</i> , 2005, 19, 1557-65; discussion 1566, 1568 passim.	0.4	1
147	The impact of targeted therapy on the treatment of colorectal cancer. <i>Oncology</i> , 2005, 19, 19-24.	0.4	2
148	A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 4, 268-274.	1.0	34
149	TRICOM: enhanced vaccines as anticancer therapy. <i>Expert Review of Vaccines</i> , 2004, 3, 397-402.	2.0	17
150	Thrombotic Thrombocytopenic Purpura as a Marker for Disease Progression in a Patient with Metastatic Rectal Cancer. <i>Blood</i> , 2004, 104, 4032-4032.	0.6	0
151	Carcinoembryonic antigen-based vaccines. <i>Seminars in Oncology</i> , 2003, 30, 30-36.	0.8	60
152	Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 2059-2069.	0.8	613
153	Phase I Study of Prolonged Infusion Bryostatatin-1 in Patients. <i>Cancer Biology and Therapy</i> , 2002, 1, 409-416.	1.5	27
154	Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report. <i>Oncology</i> , 2002, 16, 17-9.	0.4	0
155	The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 517-529.	2.0	73
156	Genetic testing for colon cancer susceptibility: Anticipated reactions of patients and challenges to providers. <i>Cancer</i> , 1996, 69, 58-61.		92
157	Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. <i>Investigational New Drugs</i> , 1996, 14, 193-202.	1.2	105
158	The clinical experience with antiangiogenic agents. <i>Breast Cancer Research and Treatment</i> , 1995, 36, 253-261.	1.1	11
159	Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. <i>American Journal of Health-System Pharmacy</i> , 1995, 52, 2570-2573.	0.5	2
160	Clinical Pharmacokinetics and Pharmacology of Trimetrexate. <i>Clinical Pharmacokinetics</i> , 1994, 26, 190-200.	1.6	21